News about "Biocon"

Biocon's Cranbury Facility in US Passes FDA Inspection, Supports Expansion Plans

Biocon’s inspection concluded with a single observation, which the company will address within the stipulated timeframe, and it is not expected to impact ongoing business operations

Biocon | 15/10/2025 | By Dineshwori

Enzene, Aurobindo and Biocon Boost US Manufacturing with Major New Jersey Expansions

This month, three leading Indian firms — Enzene Biosciences, Aurobindo Pharma, and Biocon — have inaugurated major facilities in New Jersey, underscoring a growing trend of onshore investment by Indian pharma companies.

Biocon | 18/09/2025 | By Dineshwori |  197

Biocon Opens First US Manufacturing Facility in New Jersey

The Cranbury facility will help Biocon diversify its manufacturing base, strengthen its supply chain
and accelerate the expansion of its global footprint.

Biocon | 11/09/2025 | By Dineshwori

Biocon Biologics Secures FDA Approval for Kirsty

Biocon Biologics has announced that it has received FDA approval for KIRSTY (Insulin Aspart-xjhz), making it the first and only interchangeable biosimilar to NovoLog in the US, marking a major milestone in expanding affordable insulin options.

Biocon | 16/07/2025 | By Mrinmoy Dey |  168

Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health

Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.

Biocon | 03/07/2025 | By Mrinmoy Dey |  154

Biocon Join Hands with Tabuk Pharma to Commercialize its GLP -1 Products in Middle East

The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.

Biocon | 27/09/2024 | By Aishwarya |  618

Biocon Signs Exclusive Deal for Commercializing Liraglutide in South Korea with Handok

Biocon Ltd. has signed an exclusive licensing and supply agreement with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated, complex drug product, Synthetic Liraglutide.

Biocon | 28/05/2024 | By Aishwarya |  597

Biocon Signs Semi-Exclusive Distribution and Supply Deal for with Medix

Biocon Ltd. has signed a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda).

Biocon | 13/05/2024 | By Aishwarya |  234

Biocon Signs Exclusive Licensing and Supply Deal with Biomm for Drug Commercialization

Biocon Limited has signed an exclusive licensing and supply agreement with Biomm to commercialize its vertically integrated drug product, Semaglutide (gOzempic).

Biocon | 19/04/2024 | By Aishwarya |  423

EDQM conducts GMP inspection at Biocon's API site in Bengaluru

As per the filing, the inspection was held between September 12-14, 2022 and issued a list of deficiencies on October 5, 2022

Biocon | 10/10/2022 | By Sudeep Soparkar |  424